目的探讨人工重组Clara细胞蛋白16(rhCC16)对放射性肺炎及肺纤维化的防护机制。方法将30只SD大鼠随机分成3组,对照组(n=10)、照射组(n=10)和rhCC16+照射组(n=10)。照射组和rhCC16+照射组均予单次全胸15 Gy剂量进行照射。3组均取SD大鼠...目的探讨人工重组Clara细胞蛋白16(rhCC16)对放射性肺炎及肺纤维化的防护机制。方法将30只SD大鼠随机分成3组,对照组(n=10)、照射组(n=10)和rhCC16+照射组(n=10)。照射组和rhCC16+照射组均予单次全胸15 Gy剂量进行照射。3组均取SD大鼠肺组织进行HE、Masson染色;免疫组化、Western Blot及Real Time PCR检测白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、转化生长因子β(TGF-β)、Bax以及Bcl-2的表达;ELASA检测血清中IL-6、TNF-α和TGF-β水平;Western Blot、Real Time PCR以及MTT验证rhCC16对大鼠肺泡上皮细胞的保护作用。结果与对照组比较,照射组肺组织呈现明显的炎性细胞渗出,纤维病变明显,肺泡结构破坏,细胞凋亡增多,IL-6、TNF-α以及TGF-β表达水平增高;rhCC16干预处理后病变现象明显减轻,IL-6、TNF-α以及TGF-β的表达明显降低。结论 rhCC16可以抑制辐射诱导的炎症反应、细胞凋亡以及纤维病变,对放射性肺炎及肺纤维化具有防护作用。展开更多
Hepatocellular carcinoma (HCC) is the sixth-most common cancer and the third leading cause of cancer-related death in the world. However, 40–70% patients eventually suffer from postoperative recurrence within 5 years...Hepatocellular carcinoma (HCC) is the sixth-most common cancer and the third leading cause of cancer-related death in the world. However, 40–70% patients eventually suffer from postoperative recurrence within 5 years. HCC recurrence after surgery severely affects prognosis of the patients. Nevertheless, there is an opportunity to improve patients' prognosis if doctors and researchers can recognize the importance of a standardized perioperative management and study it in clinical and pre-clinical settings. Hence, based on our own experience and published studies from other researchers, we develop this consensus regarding multidisciplinary management of locally recurrent and metastatic hepatocellular carcinoma after resection. This consensus consists of the entire course of recurrent hepatocellular carcinoma (RHCC) management, including prediction of recurrence, prevention, diagnosis, treatment and surveillance of RHCC. Consensus recommendations are presented with grades of evidences (Ia, Ib, IIa, IIb, III and IV), and strength ofrecommendations (A, B, C, D and E). We also develop a decision-making path for RHCC treatment, which can intuitively demonstrate the management for RHCC. It is hoped that we may make some effort to standardize the management of RHCC and ultimately understand how to improve outcomes.展开更多
文摘目的探讨人工重组Clara细胞蛋白16(rhCC16)对放射性肺炎及肺纤维化的防护机制。方法将30只SD大鼠随机分成3组,对照组(n=10)、照射组(n=10)和rhCC16+照射组(n=10)。照射组和rhCC16+照射组均予单次全胸15 Gy剂量进行照射。3组均取SD大鼠肺组织进行HE、Masson染色;免疫组化、Western Blot及Real Time PCR检测白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、转化生长因子β(TGF-β)、Bax以及Bcl-2的表达;ELASA检测血清中IL-6、TNF-α和TGF-β水平;Western Blot、Real Time PCR以及MTT验证rhCC16对大鼠肺泡上皮细胞的保护作用。结果与对照组比较,照射组肺组织呈现明显的炎性细胞渗出,纤维病变明显,肺泡结构破坏,细胞凋亡增多,IL-6、TNF-α以及TGF-β表达水平增高;rhCC16干预处理后病变现象明显减轻,IL-6、TNF-α以及TGF-β的表达明显降低。结论 rhCC16可以抑制辐射诱导的炎症反应、细胞凋亡以及纤维病变,对放射性肺炎及肺纤维化具有防护作用。
基金supported by Chinese Society of Liver Cancer,Chinese Medical Doctor Association and Surgical Technology Innovation and Promotion Association,NAHIEM,ChinaThis work was in part supported by grants from the State Key Scientific and Technological Research Programs(2017ZX10203207-003-0020)the Scientific and Technological Support Project of Sichuan Province(2018SZ0204,2016SZ0025 and 2015SZ0049).
文摘Hepatocellular carcinoma (HCC) is the sixth-most common cancer and the third leading cause of cancer-related death in the world. However, 40–70% patients eventually suffer from postoperative recurrence within 5 years. HCC recurrence after surgery severely affects prognosis of the patients. Nevertheless, there is an opportunity to improve patients' prognosis if doctors and researchers can recognize the importance of a standardized perioperative management and study it in clinical and pre-clinical settings. Hence, based on our own experience and published studies from other researchers, we develop this consensus regarding multidisciplinary management of locally recurrent and metastatic hepatocellular carcinoma after resection. This consensus consists of the entire course of recurrent hepatocellular carcinoma (RHCC) management, including prediction of recurrence, prevention, diagnosis, treatment and surveillance of RHCC. Consensus recommendations are presented with grades of evidences (Ia, Ib, IIa, IIb, III and IV), and strength ofrecommendations (A, B, C, D and E). We also develop a decision-making path for RHCC treatment, which can intuitively demonstrate the management for RHCC. It is hoped that we may make some effort to standardize the management of RHCC and ultimately understand how to improve outcomes.
